Praxbind: Immediate and Complete Reversal of PRADAXA® with No Procoagulant Effects1,2
Median maximum reversal in evaluable
patients was 100% in first 4 hours†
Most patients achieved complete reversal
as measured by ECT (82%), or dTT (99%)‡
*RE-VERSE AD included data for 503 patients: 301 patients with serious bleeding (Group A) and 202 requiring an urgent procedure (Group B).
†Based on determination for dTT or ECT.
‡In a limited number of patients, elevated coagulation parameters (eg, aPTT or ECT) have been observed 12-24 hours post-dose.
§Accurate as of 01/03/20, based on the current information provided to Boehringer Ingelheim Pharmaceuticals, Inc. The company cannot guarantee the availability of PRAXBIND at all facilities in every state.
References: 1. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med. 2017;377(5):431-441; 1-13 [suppl appendix]. 2. PRAXBIND [Prescribing Information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 3. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.
INDICATIONS AND USAGE FOR PRAXBIND
Praxbind® (idarucizumab) is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
- For emergency surgery/urgent procedures
- In life-threatening or uncontrolled bleeding
IMPORTANT SAFETY INFORMATION FOR PRAXBIND
WARNINGS AND PRECAUTIONS
Thromboembolic Risk
- Dabigatran-treated patients have underlying diseases predisposing them to thromboembolic events. Reversing dabigatran therapy exposes patients to thrombotic risk. Consider resumption of anticoagulant therapy as soon as medically appropriate.
Re-elevation of Coagulation Parameters
- Elevated coagulation parameters (eg, activated partial thromboplastin time or ecarin clotting time) have been observed in a limited number of PRAXBIND-treated patients. If reappearance of clinically relevant bleeding together with elevated coagulation parameters is observed, or if patients requiring a second emergency surgery/urgent procedure have elevated coagulation parameters, an additional full dose may be considered.
Hypersensitivity Reactions
- There is insufficient clinical experience evaluating risk of hypersensitivity to idarucizumab, but a possible relationship could not be excluded. Risk of hypersensitivity (eg, anaphylactoid reaction) to idarucizumab or excipients needs to be weighed cautiously against the potential benefit. If serious allergic reaction occurs, immediately discontinue PRAXBIND and institute appropriate treatment.
Risk in Patients With Hereditary Fructose Intolerance
- PRAXBIND contains 4 g sorbitol as an excipient. When prescribing PRAXBIND in patients with hereditary fructose intolerance, consider the total daily amount of sorbitol/fructose consumption from all sources, as serious adverse reactions (eg, hypoglycemia, hypophosphatemia, metabolic acidosis, increase in uric acid, acute liver failure, and death) may occur.
ADVERSE REACTIONS
- The most frequently reported adverse reaction in ≥5% of idarucizumab-treated healthy volunteers was headache (5%). The most frequently reported adverse reactions in ≥5% of patients were constipation (7%) and nausea (5%).
- Treatment-emergent antibodies with low titers were observed in 4% of healthy subjects and 2% of patients treated with idarucizumab.
USE IN SPECIFIC POPULATIONS
Pregnancy and Lactation
- PRAXBIND should be given to a pregnant woman only if clearly needed. Caution should be exercised when PRAXBIND is administered to a nursing woman.
CL-PB-100001 April 2018
Please click here for full Prescribing Information for PRAXBIND.
Leaving PRAXBIND.COM
Please Note: You are now leaving a Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) site. BIPI is not responsible for the way information is processed by sites linked to this one. Please review those sites' privacy policies and terms of use to understand how your information will be processed. Linking to any other site is at your own risk.